$MD
Pediatrix Medical Group, Inc.

2023 Q3 Form 10-Q Financial Statement

#000095017023037565 Filed on August 03, 2023

View on sec.gov

Income Statement

Concept 2023 Q3 2023 Q2
Revenue $506.6M $500.6M
YoY Change 3.41% 2.99%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $425.8M $412.0M
YoY Change 6.26% 5.13%
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization $9.211M $8.945M
YoY Change 2.85% 1.94%
% of Gross Profit
Operating Expenses $466.3M $452.1M
YoY Change 5.38% 3.72%
Operating Profit $40.27M $48.50M
YoY Change -15.01% -3.3%
Interest Expense $10.37M -$9.551M
YoY Change 9.02% -213.58%
% of Operating Profit 25.76% -19.69%
Other Income/Expense, Net -$9.440M -$9.551M
YoY Change 10.69% 34.11%
Pretax Income $30.83M $38.95M
YoY Change -20.66% -9.5%
Income Tax $9.441M $10.67M
% Of Pretax Income 30.62% 27.38%
Net Earnings $21.39M $28.28M
YoY Change -30.39% 4.22%
Net Earnings / Revenue 4.22% 5.65%
Basic Earnings Per Share $0.26 $0.34
Diluted Earnings Per Share $0.26 $0.34
COMMON SHARES
Basic Shares Outstanding 83.94M 83.76M
Diluted Shares Outstanding 82.95M 82.66M

Balance Sheet

Concept 2023 Q3 2023 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $124.7M $104.3M
YoY Change 24.64% -2.92%
Cash & Equivalents $21.18M $5.849M
Short-Term Investments $103.5M $98.49M
Other Short-Term Assets $7.866M $22.58M
YoY Change -20.54% 154.89%
Inventory
Prepaid Expenses $10.59M $12.46M
Receivables $277.4M $270.9M
Other Receivables $0.00 $0.00
Total Short-Term Assets $420.5M $397.8M
YoY Change -0.75% -13.4%
LONG-TERM ASSETS
Property, Plant & Equipment $75.15M $140.4M
YoY Change 4.87% 94.63%
Goodwill $1.532B $1.532B
YoY Change 0.0% 0.0%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $108.0M $218.4M
YoY Change -8.25% 75.61%
Total Long-Term Assets $1.906B $1.908B
YoY Change -0.13% -0.13%
TOTAL ASSETS
Total Short-Term Assets $420.5M $397.8M
Total Long-Term Assets $1.906B $1.908B
Total Assets $2.326B $2.306B
YoY Change -0.24% -2.71%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $31.70M $30.99M
YoY Change 16.8% 2.51%
Accrued Expenses $292.7M $268.3M
YoY Change -3.07% -3.45%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $14.93M $14.92M
YoY Change 0.07% -0.02%
Total Short-Term Liabilities $350.4M $320.3M
YoY Change -0.36% -2.76%
LONG-TERM LIABILITIES
Long-Term Debt $621.7M $666.3M
YoY Change -14.95% -16.01%
Other Long-Term Liabilities $31.19M $338.8M
YoY Change -26.62% 600.85%
Total Long-Term Liabilities $31.19M $1.005B
YoY Change -26.62% 1979.21%
TOTAL LIABILITIES
Total Short-Term Liabilities $350.4M $320.3M
Total Long-Term Liabilities $31.19M $1.005B
Total Liabilities $1.358B $1.363B
YoY Change -7.8% -10.57%
SHAREHOLDERS EQUITY
Retained Earnings -$25.18M -$46.58M
YoY Change -78.79% -68.84%
Common Stock $996.7M $992.5M
YoY Change 1.55% -0.5%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $968.0M $942.4M
YoY Change
Total Liabilities & Shareholders Equity $2.326B $2.306B
YoY Change -0.24% -2.71%

Cashflow Statement

Concept 2023 Q3 2023 Q2
OPERATING ACTIVITIES
Net Income $21.39M $28.28M
YoY Change -30.39% 4.22%
Depreciation, Depletion And Amortization $9.211M $8.945M
YoY Change 2.85% 1.94%
Cash From Operating Activities $79.94M $89.05M
YoY Change -4.07% 8.07%
INVESTING ACTIVITIES
Capital Expenditures $9.154M $8.131M
YoY Change -231.77% -223.99%
Acquisitions
YoY Change
Other Investing Activities -$4.850M -$2.267M
YoY Change -664.61% -66.63%
Cash From Investing Activities -$14.00M -$10.40M
YoY Change 130.03% -22.12%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -50.60M -78.93M
YoY Change -38.78% 27.01%
NET CHANGE
Cash From Operating Activities 79.94M 89.05M
Cash From Investing Activities -14.00M -10.40M
Cash From Financing Activities -50.60M -78.93M
Net Change In Cash 15.33M -275.0K
YoY Change -382.84% -103.98%
FREE CASH FLOW
Cash From Operating Activities $79.94M $89.05M
Capital Expenditures $9.154M $8.131M
Free Cash Flow $70.78M $80.92M
YoY Change -21.59% -9.04%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Central Index Key
EntityCentralIndexKey
0000893949
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-12111
dei Entity Registrant Name
EntityRegistrantName
Pediatrix Medical Group, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
FL
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
26-3667538
dei Entity Address Address Line1
EntityAddressAddressLine1
1301 Concord Terrace
dei Entity Address City Or Town
EntityAddressCityOrTown
Sunrise
dei Entity Address State Or Province
EntityAddressStateOrProvince
FL
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
33323
dei City Area Code
CityAreaCode
954
dei Local Phone Number
LocalPhoneNumber
384-0175
dei Security12b Title
Security12bTitle
Common Stock, par value $.01 per share
dei Trading Symbol
TradingSymbol
MD
dei Security Exchange Name
SecurityExchangeName
NYSE
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
83941842
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
5849000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
9824000
CY2023Q2 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
98490000
CY2022Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
93239000
CY2023Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
270852000
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
296787000
CY2023Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
12461000
CY2022Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
14878000
CY2023Q2 us-gaap Other Assets Current
OtherAssetsCurrent
10115000
CY2022Q4 us-gaap Other Assets Current
OtherAssetsCurrent
13261000
CY2023Q2 us-gaap Assets Current
AssetsCurrent
397767000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
427989000
CY2023Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
73334000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
73290000
CY2023Q2 us-gaap Goodwill
Goodwill
1532092000
CY2022Q4 us-gaap Goodwill
Goodwill
1532092000
CY2023Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
16800000
CY2022Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
18491000
CY2023Q2 md Operating And Finance Lease Right Of Use Assets
OperatingAndFinanceLeaseRightOfUseAssets
67088000
CY2022Q4 md Operating And Finance Lease Right Of Use Assets
OperatingAndFinanceLeaseRightOfUseAssets
66924000
CY2023Q2 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
101600000
CY2022Q4 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
105925000
CY2023Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
116829000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
123176000
CY2023Q2 us-gaap Assets
Assets
2305510000
CY2022Q4 us-gaap Assets
Assets
2347887000
CY2023Q2 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
277680000
CY2022Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
374225000
CY2023Q2 us-gaap Long Term Debt And Capital Lease Obligations Current
LongTermDebtAndCapitalLeaseObligationsCurrent
14919000
CY2022Q4 us-gaap Long Term Debt And Capital Lease Obligations Current
LongTermDebtAndCapitalLeaseObligationsCurrent
14898000
CY2023Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
21567000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
21589000
CY2023Q2 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
6152000
CY2022Q4 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
16271000
CY2023Q2 us-gaap Liabilities Current
LiabilitiesCurrent
320318000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
426983000
CY2023Q2 us-gaap Line Of Credit
LineOfCredit
41000000
CY2022Q4 us-gaap Line Of Credit
LineOfCredit
4000000
CY2023Q2 us-gaap Long Term Debt And Capital Lease Obligations
LongTermDebtAndCapitalLeaseObligations
625273000
CY2022Q4 us-gaap Long Term Debt And Capital Lease Obligations
LongTermDebtAndCapitalLeaseObligations
632381000
CY2023Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
43066000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
44213000
CY2023Q2 us-gaap Malpractice Loss Contingency Accrual Undiscounted Noncurrent
MalpracticeLossContingencyAccrualUndiscountedNoncurrent
263784000
CY2022Q4 us-gaap Malpractice Loss Contingency Accrual Undiscounted Noncurrent
MalpracticeLossContingencyAccrualUndiscountedNoncurrent
275629000
CY2023Q2 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
37767000
CY2022Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
33638000
CY2023Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
31927000
CY2022Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
39411000
CY2023Q2 us-gaap Liabilities
Liabilities
1363135000
CY2022Q4 us-gaap Liabilities
Liabilities
1456255000
CY2023Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000
CY2023Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q2 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2023Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
83841000
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
83841000
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
82947000
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
82947000
CY2023Q2 us-gaap Common Stock Value
CommonStockValue
838000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
829000
CY2023Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
991630000
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
983601000
CY2023Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-3518000
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-3735000
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-46575000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-89063000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
942375000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
891632000
CY2023Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
2305510000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
2347887000
CY2023Q2 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
500577000
CY2022Q2 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
486033000
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
991585000
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
968262000
CY2023Q2 md Practice Salaries And Benefits
PracticeSalariesAndBenefits
354032000
CY2022Q2 md Practice Salaries And Benefits
PracticeSalariesAndBenefits
330757000
md Practice Salaries And Benefits
PracticeSalariesAndBenefits
716267000
md Practice Salaries And Benefits
PracticeSalariesAndBenefits
673912000
CY2023Q2 md Practice Supplies And Other Operating Expenses
PracticeSuppliesAndOtherOperatingExpenses
31089000
CY2022Q2 md Practice Supplies And Other Operating Expenses
PracticeSuppliesAndOtherOperatingExpenses
29843000
md Practice Supplies And Other Operating Expenses
PracticeSuppliesAndOtherOperatingExpenses
61809000
md Practice Supplies And Other Operating Expenses
PracticeSuppliesAndOtherOperatingExpenses
58332000
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
58013000
CY2022Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
61165000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
117072000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
122452000
CY2023Q2 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
8945000
CY2022Q2 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
8775000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
17898000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
17544000
CY2023Q2 us-gaap Restructuring Charges
RestructuringCharges
0
CY2022Q2 us-gaap Restructuring Charges
RestructuringCharges
5338000
us-gaap Restructuring Charges
RestructuringCharges
0
us-gaap Restructuring Charges
RestructuringCharges
6759000
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
452079000
CY2022Q2 us-gaap Operating Expenses
OperatingExpenses
435878000
us-gaap Operating Expenses
OperatingExpenses
913046000
us-gaap Operating Expenses
OperatingExpenses
878999000
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
48498000
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
50155000
us-gaap Operating Income Loss
OperatingIncomeLoss
78539000
us-gaap Operating Income Loss
OperatingIncomeLoss
89263000
CY2023Q2 us-gaap Investment Income Net
InvestmentIncomeNet
1189000
CY2022Q2 us-gaap Investment Income Net
InvestmentIncomeNet
844000
us-gaap Investment Income Net
InvestmentIncomeNet
1823000
us-gaap Investment Income Net
InvestmentIncomeNet
1719000
CY2023Q2 us-gaap Interest Expense
InterestExpense
11230000
CY2022Q2 us-gaap Interest Expense
InterestExpense
8409000
us-gaap Interest Expense
InterestExpense
21620000
us-gaap Interest Expense
InterestExpense
20227000
CY2023Q2 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0
CY2022Q2 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-57016000
CY2023Q2 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
490000
CY2022Q2 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
443000
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
917000
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
948000
CY2023Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-9551000
CY2022Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-7122000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-18880000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-74576000
CY2023Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
38947000
CY2022Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
43033000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
59659000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
14687000
CY2023Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
10665000
CY2022Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
12332000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
17171000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
4931000
CY2023Q2 us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
28282000
CY2022Q2 us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
30701000
us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
42488000
us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
9756000
CY2023Q2 us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
0
CY2022Q2 us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
-3565000
us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
0
us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
-3812000
CY2023Q2 us-gaap Profit Loss
ProfitLoss
28282000
CY2022Q2 us-gaap Profit Loss
ProfitLoss
27136000
us-gaap Profit Loss
ProfitLoss
42488000
us-gaap Profit Loss
ProfitLoss
5944000
CY2023Q2 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
0
CY2022Q2 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
0
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
0
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-4000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
28282000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
27136000
us-gaap Net Income Loss
NetIncomeLoss
42488000
us-gaap Net Income Loss
NetIncomeLoss
5948000
CY2023Q2 us-gaap Other Comprehensive Income Availableforsale Securities Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesTaxPortionAttributableToParent
126000
CY2022Q2 us-gaap Other Comprehensive Income Availableforsale Securities Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesTaxPortionAttributableToParent
414000
us-gaap Other Comprehensive Income Availableforsale Securities Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesTaxPortionAttributableToParent
353000
us-gaap Other Comprehensive Income Availableforsale Securities Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesTaxPortionAttributableToParent
1308000
CY2023Q2 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-387000
CY2022Q2 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-1234000
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
217000
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-3902000
CY2023Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
27895000
CY2022Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
25902000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
42705000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
2046000
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.34
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.32
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.52
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.07
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.34
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.32
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.52
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.07
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
82399000
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
85078000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
82033000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
85190000
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
82664000
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
85619000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
82377000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
85914000
CY2022Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
891632000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
14206000
CY2023Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
604000
CY2023Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
1095000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3009000
CY2023Q1 us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
775000
CY2023Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
909771000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
28282000
CY2023Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-387000
CY2023Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
1594000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3126000
CY2023Q2 us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
11000
CY2023Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
942375000
CY2021Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
896692000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-21188000
CY2022Q1 md Dissolution Of And Net Income Loss Attributable To Noncontrolling Interest
DissolutionOfAndNetIncomeLossAttributableToNoncontrollingInterest
-203000
CY2022Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-2668000
CY2022Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
1174000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4435000
CY2022Q1 us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
1166000
CY2022Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
877076000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
27136000
CY2022Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-1234000
CY2022Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
1664000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5186000
CY2022Q2 us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
64398000
CY2022Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
845430000
us-gaap Net Income Loss
NetIncomeLoss
42488000
us-gaap Net Income Loss
NetIncomeLoss
5948000
us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
0
us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
-3812000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
17898000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
17544000
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
733000
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
857000
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-57016000
us-gaap Share Based Compensation
ShareBasedCompensation
6135000
us-gaap Share Based Compensation
ShareBasedCompensation
8771000
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
8376000
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-1894000
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
900000
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
1577000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-28900000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
15950000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-2141000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-17044000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-5052000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-6970000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-97315000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-90986000
us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
-12028000
us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
-12254000
us-gaap Increase Decrease In Liability For Claims And Claims Adjustment Expense Reserve
IncreaseDecreaseInLiabilityForClaimsAndClaimsAdjustmentExpenseReserve
838000
us-gaap Increase Decrease In Liability For Claims And Claims Adjustment Expense Reserve
IncreaseDecreaseInLiabilityForClaimsAndClaimsAdjustmentExpenseReserve
-2768000
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-10356000
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-867000
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-8038000
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-8334000
us-gaap Cash Provided By Used In Operating Activities Discontinued Operations
CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations
-3825000
us-gaap Cash Provided By Used In Operating Activities Discontinued Operations
CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations
-6741000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-11863000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-15075000
us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
1667000
us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
28167000
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
17761000
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
12983000
us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
12810000
us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
14039000
us-gaap Payments To Acquire Other Property Plant And Equipment
PaymentsToAcquireOtherPropertyPlantAndEquipment
15130000
us-gaap Payments To Acquire Other Property Plant And Equipment
PaymentsToAcquireOtherPropertyPlantAndEquipment
13703000
us-gaap Proceeds From Sale Of Other Productive Assets
ProceedsFromSaleOfOtherProductiveAssets
0
us-gaap Proceeds From Sale Of Other Productive Assets
ProceedsFromSaleOfOtherProductiveAssets
1189000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-21748000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-39625000
us-gaap Proceeds From Lines Of Credit
ProceedsFromLinesOfCredit
421000000
us-gaap Proceeds From Lines Of Credit
ProceedsFromLinesOfCredit
475000000
us-gaap Repayments Of Lines Of Credit
RepaymentsOfLinesOfCredit
384000000
us-gaap Repayments Of Lines Of Credit
RepaymentsOfLinesOfCredit
321500000
md Payments To Term Loan
PaymentsToTermLoan
6250000
md Payments To Term Loan
PaymentsToTermLoan
3125000
us-gaap Repayments Of Senior Debt
RepaymentsOfSeniorDebt
0
us-gaap Repayments Of Senior Debt
RepaymentsOfSeniorDebt
1046880000
us-gaap Proceeds From Issuance Of Senior Long Term Debt
ProceedsFromIssuanceOfSeniorLongTermDebt
0
us-gaap Proceeds From Issuance Of Senior Long Term Debt
ProceedsFromIssuanceOfSeniorLongTermDebt
650000000
us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
0
us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
8394000
md Repayments Of Long Term Capital Lease Obligation
RepaymentsOfLongTermCapitalLeaseObligation
1404000
md Repayments Of Long Term Capital Lease Obligation
RepaymentsOfLongTermCapitalLeaseObligation
1262000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
2689000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
2838000
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
786000
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
65564000
us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
-1613000
us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
284000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
29636000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-318603000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-3975000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-373303000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
9824000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
387391000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
5849000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
14088000
CY2023Q2 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
98490000
CY2022Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
93239000
CY2023Q2 us-gaap Accounts Receivable Gross Current
AccountsReceivableGrossCurrent
1409118000
CY2022Q4 us-gaap Accounts Receivable Gross Current
AccountsReceivableGrossCurrent
1548492000
CY2023Q2 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
1138266000
CY2022Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
1251705000
CY2023Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
270852000
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
296787000
CY2023Q2 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
500577000
CY2022Q2 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
486033000
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
991585000
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
968262000
CY2023Q2 md Percentage Of Net Patient Service Revenue By Type Of Payor
PercentageOfNetPatientServiceRevenueByTypeOfPayor
1
CY2022Q2 md Percentage Of Net Patient Service Revenue By Type Of Payor
PercentageOfNetPatientServiceRevenueByTypeOfPayor
1
md Percentage Of Net Patient Service Revenue By Type Of Payor
PercentageOfNetPatientServiceRevenueByTypeOfPayor
1
md Percentage Of Net Patient Service Revenue By Type Of Payor
PercentageOfNetPatientServiceRevenueByTypeOfPayor
1
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
82377000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
85914000
CY2023Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1338000
CY2022Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
569000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1358000
CY2023Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
30992000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
31857000
CY2023Q2 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
116869000
CY2022Q4 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
197831000
CY2023Q2 md Accrued Payroll Taxes And Benefits Current
AccruedPayrollTaxesAndBenefitsCurrent
31205000
CY2022Q4 md Accrued Payroll Taxes And Benefits Current
AccruedPayrollTaxesAndBenefitsCurrent
34983000
CY2023Q2 us-gaap Malpractice Loss Contingency Accrual Undiscounted Current
MalpracticeLossContingencyAccrualUndiscountedCurrent
29001000
CY2022Q4 us-gaap Malpractice Loss Contingency Accrual Undiscounted Current
MalpracticeLossContingencyAccrualUndiscountedCurrent
32232000
CY2023Q2 us-gaap Interest Payable Current
InterestPayableCurrent
9370000
CY2022Q4 us-gaap Interest Payable Current
InterestPayableCurrent
8921000
CY2023Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
60243000
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
68401000
CY2023Q2 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
277680000
CY2022Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
374225000
md Increase Decrease In Accrued Salaries And Bonuses
IncreaseDecreaseInAccruedSalariesAndBonuses
80900000
CY2023Q2 us-gaap Debt Instrument Interest Rate Stated Percentage
DebtInstrumentInterestRateStatedPercentage
0.05375
us-gaap Debt Instrument Frequency Of Periodic Payment
DebtInstrumentFrequencyOfPeriodicPayment
payable semi-annually in arrears on February 15 and August 15, beginning on August 15, 2022
us-gaap Debt Instrument Description
DebtInstrumentDescription
Notes are guaranteed on an unsecured senior basis by the same subsidiaries and affiliated professional contractors that guarantee the Amended Credit Agreement (as defined below). The indenture under which the 2030 Notes are issued, among other things, limits the Company's ability to (1) incur liens and (2) enter into sale and lease-back transactions, and also limits the Company's ability to merge or dispose of all or substantially all of its assets, in all cases, subject to a number of customary exceptions
CY2023Q2 md Purchase Price
PurchasePrice
1.01
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
82399000
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
85078000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
82033000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
85190000
CY2023Q2 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
265000
CY2022Q2 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
541000
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
344000
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
724000
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
82664000
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
85619000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
409000
CY2023Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3100000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6100000
CY2022Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4400000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
8800000
us-gaap Stock Repurchased During Period Shares
StockRepurchasedDuringPeriodShares
0
CY2018Q3 us-gaap Stock Repurchase Program Authorized Amount1
StockRepurchaseProgramAuthorizedAmount1
500000000
CY2018Q3 us-gaap Stock Repurchase Program Remaining Authorized Repurchase Amount1
StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1
5500000
CY2023Q2 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
CY2023Q2 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2023Q2 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false

Files In Submission

Name View Source Status
0000950170-23-037565-index-headers.html Edgar Link pending
0000950170-23-037565-index.html Edgar Link pending
0000950170-23-037565.txt Edgar Link pending
0000950170-23-037565-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
img259346392_0.jpg Edgar Link pending
md-20230630.htm Edgar Link pending
md-20230630.xsd Edgar Link pending
md-ex31_1.htm Edgar Link pending
md-ex31_2.htm Edgar Link pending
md-ex32_1.htm Edgar Link pending
md-ex3_1.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
md-20230630_cal.xml Edgar Link unprocessable
md-20230630_def.xml Edgar Link unprocessable
md-20230630_lab.xml Edgar Link unprocessable
md-20230630_pre.xml Edgar Link unprocessable
md-20230630_htm.xml Edgar Link completed
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending